ATE359089T1 - Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus - Google Patents

Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus

Info

Publication number
ATE359089T1
ATE359089T1 AT03010010T AT03010010T ATE359089T1 AT E359089 T1 ATE359089 T1 AT E359089T1 AT 03010010 T AT03010010 T AT 03010010T AT 03010010 T AT03010010 T AT 03010010T AT E359089 T1 ATE359089 T1 AT E359089T1
Authority
AT
Austria
Prior art keywords
peptides
virus
cytotoxic
against hepatitis
induring
Prior art date
Application number
AT03010010T
Other languages
English (en)
Inventor
Francis V Chisari
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE359089T1 publication Critical patent/ATE359089T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/223—Hepatitis related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03010010T 1993-02-26 1994-02-25 Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus ATE359089T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2412093A 1993-02-26 1993-02-26

Publications (1)

Publication Number Publication Date
ATE359089T1 true ATE359089T1 (de) 2007-05-15

Family

ID=21818965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03010010T ATE359089T1 (de) 1993-02-26 1994-02-25 Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus

Country Status (11)

Country Link
US (1) US5788969A (de)
EP (2) EP0687182B1 (de)
JP (2) JP3657603B2 (de)
KR (1) KR960700745A (de)
CN (1) CN1118573A (de)
AT (1) ATE359089T1 (de)
AU (1) AU695261B2 (de)
DE (2) DE69434954T2 (de)
ES (1) ES2204912T3 (de)
NZ (1) NZ263030A (de)
WO (1) WO1994019011A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6235288B1 (en) * 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO1999036434A1 (en) * 1998-01-19 1999-07-22 Mogam Biotechnology Research Institute Liposomes comprising peptide antigens derived from x protein of hepatitis b virus
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US20040037843A1 (en) * 1999-12-21 2004-02-26 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
KR100455902B1 (ko) * 2001-07-18 2004-11-12 주식회사 펩트론 Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드
CN1305527C (zh) * 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
EP1982992B1 (de) 2006-02-07 2010-10-27 NEC Corporation Hla bindendes peptid, dessen vorstufe, dafür codierendes dna-fragment und rekombinanter vektor
EP2085474A4 (de) 2006-10-12 2010-12-01 Nec Corp Hla bindendes peptid, dessen vorstufe, dafür codierendes dna-fragment und rekombinanter vektor
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
EP0293201A3 (de) * 1987-05-26 1990-02-28 The Wistar Institute Methode zur Impfung gegen Hepatitis-B-Virus
EP0326111A3 (de) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptid-Derivate, immunogenisch gemacht bei Verabreichung zusammen mit Alaun als Zusatzmittel
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
EP0726941B1 (de) * 1993-08-06 2002-04-03 Epimmune Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl

Also Published As

Publication number Publication date
WO1994019011A1 (en) 1994-09-01
EP0687182B1 (de) 2003-08-06
EP0687182A4 (de) 1997-03-12
EP1375511A2 (de) 2004-01-02
AU6355994A (en) 1994-09-14
AU695261B2 (en) 1998-08-13
CN1118573A (zh) 1996-03-13
EP0687182A1 (de) 1995-12-20
JP3657603B2 (ja) 2005-06-08
NZ263030A (en) 1997-10-24
ES2204912T3 (es) 2004-05-01
EP1375511A3 (de) 2005-03-02
DE69434954T2 (de) 2007-12-20
KR960700745A (ko) 1996-02-24
DE69434954D1 (de) 2007-05-24
US5788969A (en) 1998-08-04
JP2004161778A (ja) 2004-06-10
DE69433007T2 (de) 2004-06-09
EP1375511B1 (de) 2007-04-11
JPH08507080A (ja) 1996-07-30
DE69433007D1 (de) 2003-09-11
JP3616390B2 (ja) 2005-02-02

Similar Documents

Publication Publication Date Title
ATE227118T1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
DE69434954D1 (de) Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
DE69016956D1 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
FI894580A7 (fi) Non-A, non-B-hepatitisvirusantigeenipeptidi
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
FR2632863B2 (fr) Virus du fowlpox recombinant et vaccins derives de ces virus
FI931393A7 (fi) Peptidit käytettäväksi rokotuksessa ja neutraloivien vasta-aineiden in duktiossa ihmisen immuunikadon aiheuttavaa virusta vastaan
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
ITRM910546A1 (it) Epitopi della proteina env del virus dell'epatite c.
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DK0498905T3 (da) Tilpassede epitoper af human immundeficiensvirus kappeglycoprotein gp120
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
KR900016262A (ko) 포유류 중의 HIV-억제 항체 유도성 사람 면역 결핍 바이러스(HIV) env-암호화된 펩타이드
FI930519A7 (fi) Peptiidejä HIV-viruksen aiheuttaman infektion torjumiseksi sekä menete lmä niiden käyttämiseksi
IT8721644A0 (it) Procedimento per l'ottenimento di un vaccino ricombinante contro l'epatite b.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties